Richard Chen Mao
Direttore/Membro del Consiglio presso Stimwave Technologies, Inc.
Profilo
Richard Chen Mao currently works at Stimwave Technologies, Inc., as Director.
Posizioni attive di Richard Chen Mao
Società | Posizione | Inizio |
---|---|---|
Stimwave Technologies, Inc.
Stimwave Technologies, Inc. BiotechnologyHealth Technology Part of Curonix LLC, Stimwave Technologies, Inc. is a privately held medical device company based in Pompano Beach, FL. Stimwave specializes in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators. These miniature neurostimulators offer patients a convenient, safe, minimally invasive, and cost-effective solution for pain management. The company's goal is to become the leading provider of neuromodulation technology, making it more accessible to patients globally and reducing the economic burden of pain management. Stimwave's FDA-cleared product portfolio includes peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) products that provide a drug-free alternative for treating chronic pain by blocking pain signals to the brain. The CEO of the company is Aure Bruneau. Stimwave operates worldwide through its operating subsidiaries and was acquired by Curonix LLC on November 01, 2022. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Stimwave Technologies, Inc.
Stimwave Technologies, Inc. BiotechnologyHealth Technology Part of Curonix LLC, Stimwave Technologies, Inc. is a privately held medical device company based in Pompano Beach, FL. Stimwave specializes in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators. These miniature neurostimulators offer patients a convenient, safe, minimally invasive, and cost-effective solution for pain management. The company's goal is to become the leading provider of neuromodulation technology, making it more accessible to patients globally and reducing the economic burden of pain management. Stimwave's FDA-cleared product portfolio includes peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) products that provide a drug-free alternative for treating chronic pain by blocking pain signals to the brain. The CEO of the company is Aure Bruneau. Stimwave operates worldwide through its operating subsidiaries and was acquired by Curonix LLC on November 01, 2022. | Health Technology |
- Borsa valori
- Insiders
- Richard Chen Mao